Medicaid holiday cheer for pharmacy
Executive Summary
Medicaid's Internet publication of new average manufacturer prices and use of AMPs to set payment limits will be blocked temporarily, under a preliminary injunction granted Dec. 14. The U.S. District Court for D.C. will hear the suit against the AMP rules, filed by the National Community Pharmacists Association and National Association of Chain Drug Stores (1"The Pink Sheet" Nov. 12, 2007, p. 26)...
You may also be interested in...
Medicaid AMP lawsuit delayed
A lawsuit seeking to block CMS from implementing a rule that would reimburse pharmacies 250 percent of the average manufacturer price for the least expensive drug in a multi-source group has been delayed because of the change of administration in the White House. The National Association of Chain Drug Stores, the National Community Pharmacists Association (who brought the original suit to keep the regulations from going into effect) and HHS requested the delay since CMS has yet to resolve any regulatory issues related to the definition of "multiple source drug." A hearing on the case had been scheduled for Feb. 25. Participants in the case do not expect action until at least the middle of May. A judge in the case granted a temporary injunction to prevent the rule from going into effect (1"The Pink Sheet," Dec. 17, 2007, In Brief). The Medicare Improvements for Patients and Providers Act delayed implementation of the rule through Sept. 30, 2009 (2"The Pink Sheet," July 21, 2008, p. 21). During the debate on the economic stimulus package in the Senate, Sens. Blanche Lincoln, D-Ark., and Debbie Stabenow, D-Mich., introduced an amendment that would have extended the delay through June 30, 2010, but no action was taken
Medicaid AMPs Should Be Limited To A-Rated Drugs – Pharmacy Lawsuit
Medicaid's drug payment limits will be applied illegally to non-equivalent drugs under the program's average manufacturer price rules, the National Association of Chain Drug Stores and National Community Pharmacists Association argue in a lawsuit filed Nov. 7
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.